Can-Fite BioPharma announced that it has dosed the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. The study will enroll 78 patients with refractory advanced hepatocellular carcinoma  with Child-Pugh Class B cirrhosis. Patients will receive 25 mg of CF102 orally twice a day; the endpoint will be overall survival between those receiving CF102 versus placebo. Continue reading →